The target IOP is the mean IOP obtained with treatment that prevents further glaucomatous damage in the eye of the individual under consideration. The.

Slides:



Advertisements
Similar presentations
Welcome to CNIB’s InFocus Webinar Series
Advertisements

Paras Guide to Glaucoma
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Serum Lipids and Proliferative Diabetic Retinopathy Klein BEK, Myers CE, Howard.
ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.
Introduction Glaucoma starting from the definition, unknown etiology for the primary cases, glaucoma suspect, ocular hypertension, early detection, diagnosis,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May-June 2008.
0 Glaucoma can take your sight away. Keep Vision in Your Future.
In the name of god Target IOP S.M.Shahshahan M.D Feb 2010.
Phacoemulsification with Goniosynechialysis in the Management of Refractory Acute Angle-closure Glaucoma Ghasem Fakhraie*, MD, Mahmoud Jabbarvand, MD,
The Diabetic Retinopathy Clinical Research Network Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for.
The Canadian Association of Optometrists
Cataract in the 21st century Liana Al-Labadi, O.D. Lecture 6 Thanks To The Ohio State College of Optometry.
OPEN ANGLE GLAUCOMA Frank J. Weinstock, MD, FACS Professor of Ophthalmology- NEOUCOM Canton, Ohio USA.
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Retinal Nerve Fiber Layer Loss and Quality of Life in Glaucoma Gracitelli CPB,
Variations in corneal biomechanical parameters and central corneal thickness during the menstrual cycle. David Zadok, MD, Yakov Goldich, MD, Yaniv Barkana,
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Will my Glaucoma patient lose vision ?
RANDOMIZED CLINICAL TRIALS IN GLAUCOMA- WHAT DO THEY TELL US? Dr Jyoti Shetty B.W.Lions superspeciality eye hospital.
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
QUANTITATING THE IMPACT OF CLINICAL AND BASIC SCIENCE RESEARCH POSTER #2469 M. O. GORDON, C. SARLI, E. K. DUBINSKY, E. LONG, C. LA RUE, M. A. KASS, AND.
Universita’ di Catania, Italia Clinica Oculistica Dir.: Prof. A. Reibaldi Purpose: To evaluate the efficacy and safety of Pneumotrabeculoplasty (PNT) in.
Does Greater Long-Term IOP Variability Increase Probability of Primary Open Angle Glaucoma in the Ocular Hypertension Treatment Study (OHTS)? M.O. Gordon,
Effect of Corneal Thickness on Selective Laser Trabeculoplasty to Decrease Intraocular Pressure as Primary or Secondary Treatment of Glaucoma ASCRS 2010.
A Randomized Trial of Peribulbar Triamcinolone Acetonide with and without Focal Photocoagulation for Mild Diabetic Macular Edema: A Pilot Study.
How Do I Know My Glaucoma Treatment is Working? Dr Catherine Green Head: Glaucoma Unit RVEEH.
Effect of Race on Selective Laser Trabeculoplasty  1st author has no financial interest in the subject matter of this poster.  2nd and 3rd co-authors.
Introduction  Selective Laser Trabeculoplasty (SLT) uses a Q-Switched frequency- doubled (532 nm), low energy Nd:YAG laser, which targets melanocytes.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Blindness or low vision effects more than 3 million Americans 40 years and older, and this number is projected to reach 5.5 million by In addition.
E-Poster Rio de Janeiro Corneal Tomography and Biomechanics Study Group The study of the correlations of the optic disc size with Cornal Geometry and Biomechanical.
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Sponsored by the National Eye Institute,
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
Effect of East Asian Race on Selective Laser Trabeculoplasty ASCRS 2011 Minerva Kim Johns Hopkins University Lawrence F. Jindra, MD Columbia University.
Effect of Refractive State on Selective Laser Trabeculoplasty ASCRS 2011 Kevin Lai Stony Brook University School of Medicine Elaine M. Miglino Floral Park.
Bromfenac Sodium Hydrate is Effective in Treating Intraoperative Discomfort during Selective Laser Trabeculoplasty ASCRS 2009 Marie T. Natale Floral Park.
Elmira Baghdasaryan1,2, M.D. Sophie X. Deng1, M.D., Ph.D.
Dorzolamide A topical Carbonic anhydrase inhibitor. Ampholytic characteristics, hence good corneal penetration (depot effect achieved in cornea). Achieves.
Glaucoma studies, IOP and treatment rationale W. H. Morgan RPH, LEI and PMH.
Mr. A. Waldock MD BMed Sci (Hons) BM BS FRCOphth Consultant Ophthalmic Surgeon Ophthalmology Training Programme Director, East of England Deanery.
The Royal Victorian Eye and Ear Hospital 24-hour eye pressure and glaucoma Dr Simon Skalicky FRANZCO, MPhil, MMed (Ophthal Sci), MBBS (Hons 1) Visiting.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genetic Risk of Primary Open-angle Glaucoma: Population-Based.
Six-Year Longevity of Selective Laser Trabeculoplasty as Primary Therapy in Patients with Glaucoma ASCRS 2009 Lawrence F. Jindra, MD Columbia University.
Effect of Previous Argon Laser Trabeculoplasty on Selective Laser Trabeculoplasty ASCRS 2011 Lawrence F. Jindra, MD Columbia University Winthrop University.
Glaucoma Lily T. Im, MD. What is glaucoma?   Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness.
A Deeper Look at Sight Threatening Conditions: Glaucoma, Macular Degeneration, and Diabetic Retinopathy Ashley S. Reddell, OD, FCOVD HOACLS 2015.
(Relates to Chapter 22, “Nursing Management: Visual and Auditory Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier.
Understanding Glauco ma. Femi Babalola Rachel eye center Garki, Abuja.
María Alejandra Carrasco, MD Mendoza. Argentina
The Efficacy and Safety of the Low Intensity Ultrasound Treatment in Patients with Open Angle Glaucoma Hyoung Won Bae, Gong Je Seong, Chan Yun Kim Institute.
Iwona Helemejko, MD 1; D. Robert Iskander, PhD2
PROTECTING CELLS IN THE EYE AT RISK OF DAMGE FROM GLAUCOMA
Tulsi Changulani 1,*, Jenny Bo 2, Mei-Ling Cheng 1, Andrew Tatham 1
Target IOP Update Mohamed Yasser Sayed Saif Beni Suef University
Safety of medication reduction for Primary Angle Closure (PAC) –
Glaucoma Suspect - Shields Textbook of Glaucoma, 6th edition - 녹내장 개정5판, 한국녹내장학회 부천성모병원 안과 Ap.홍승우/R3 이국.
Review of Glaucoma Suspect
Early Intraocular Pressure Rise After Phacoemulsification In Non-Glaucomatous And Eyes With Primary Open-Angle Glaucoma Milos Todorovic 1, Suncica Sreckovic.
Neuroretinal Rim Recovery In Narrow Angle Glaucoma After Intraocular Pressure Lowering With Topical Medications  – Case Report Božić M.1,2, Marković V.
Effect of Selective Laser Trabeculoplasty on
From: The Effects of Study Design and Spectrum Bias on the Evaluation of Diagnostic Accuracy of Confocal Scanning Laser Ophthalmoscopy in Glaucoma Invest.
Winthrop University Hospital
Clinical Cases in Glaucoma Treatment
Associate Professor of Ophthalmology
Winthrop University Hospital
ASCRS 2010 Joseph A. Donnelly Albert Einstein College of Medicine
Box and whiskers plot for bIOP, Goldmann applanation tonometry IOP (GAT) and Goldmann adjusted (GATAdj) in ocular hypertension (OHT), primary open-angle.
Presentation transcript:

The target IOP is the mean IOP obtained with treatment that prevents further glaucomatous damage in the eye of the individual under consideration. The main problems of target IOP assessment are: it must be individualized to the patient and to each eye; it should be an accurate estimate it needs to be determined in advance. Estimation of the target IOP A) For any individual who has unquestionable damage as a result of glaucoma, but in the early stage (see Hodapp's grading system),“ a_20% decrease in IOP is advisable. For moderate and advance damage, a 30 and 40% decrease of IOP from baseline, respectively, is proposed. In addition to glaucoma damage stage, one can also consider recognized risk factors for further progression. B) The initial IOP is related to the cup disc changes as well as the field in four grades using a simple formula [(max. IOP - % reduction) – Z] and Z depends on the disc or field damage C)Traverso C E, proposed to add a further 3% IOP lowering for each risk factor or for each decade of life expectancy; no more than four factors are to be added, however. D) other methods described take in consideration the risk factors in detail It is useful, however, to think in terms of an algorithm to rationalize the need for individualized IOP goals in each eye of each patient. A better definition of true risk factors for progression and of life expectancy are mandatory for the application of this algorithm.( Traverso C E) What is new? We are providing in this study a proposal for estimation of the target IOP individualized for each eye, determined accurately in advance as demanded by Traverso. how ? The risk factors for getting glaucoma include age, race, sex, heredity, family history, systemic (Diabetes, Obesity, Hypertension, Hypotension, arteriosclerosis and smoking) and socioeconomic factors as well as local factors (myopia, corneal thickness and scleral rigidity) all will channel into the resultant level of IOP and disc damage. So calculation of the combined probability of getting glaucoma for these 2 factors alone will include all the above mentioned variables. Table Subjects and methods The cases introduced will scan most of our clinical need to estimate the target IOP Target IOP In cases in whom treatment is necessary we have to achieve the target IOP Our target IOP is to reduce the pressure to a probability of 0.10 or maximally 0.20 if it is possible taking in consideration that the IOP has to be corrected for any change in the corneal thickness or scleral rigidity. The target pressure in our study is related to the C/D ratio (corrected). (table 2) Management Normal:nothing to be done Possible :observe Probable: treat and observe Highly probable: treatment vigorously & observe Definite: full tolerable treatment, laser or surgery & observe ReferencesReferences : 1.. Carlo E Traverso. Identifying the target intraocular pressure and adjusting treatment In Robert N Weinreb, Yoshiaki Kitazawa, Günther K Krieglstein, ; Glaucoma in the 21 st Century ; Mosby International Ltd 2000 published by Harcourt Health communication 2.Collaborative Normal ‑ Tension Glaucoma Study Group. Comparison of glaucoma progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487 ‑ Collaborative Normal ‑ Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal ‑ tension glaucoma. Am j Ophthalmol 1998;126:498 ‑ Traverso CE, Semino E, Morescalchi S, et al. Is the visual field of patients with advanced POAG protected by lowering the IOP? In: Mills RP, Wall M, eds. Perimetry update 1994/1995. Amsterdam: Kugler; 1995:309 ‑ Devindra Sood, NN Sood ‘ primary open angle glaucoma, Modern Ophthalmology 3 rd Edition, Editor LC Dutta, publisher Jaypee. Vol 1 Ch 66 page Saif SSEH, Saif MYS, Saif ATS. Early Detection of Glaucoma, A New Scoring System; Bull. Ophthalmol. Soc. Egypt,2005;vol 98,number 3, Davanger M, Ringvold A, Bilka S. The probability of having glaucoma at different IOP levels. Acta Ophthalmol. 1991;69: Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology Apr;105(4): Mao LK, Steward LC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open ‑ angle glaucoma. Am J Ophthalmol 1991;111:51 ‑ 55. Target Intraocular pressure What is new? Prof Dr Sayed S. E. H. Saif, MD ; Dr M. Yasser S Saif, MD ; Dr Ahmed T.S. Saif, MD Professor of Ophthalmology, Cairo University Lecturer of Ophthalmology, Beni Sweif University Lecturer of Ophthalmology, Fayoum University Figure 1 demonstrates the probability of getting glaucoma (Y1)in relation to the IOP(X) and its derived equationY1=Y0+A1eX/T1 Y1= the probability of the incidence of POAG in the next 5 years when the IOP = x1 ( modified from Davanger M, Ringvold A, Bilka S. The probability of having glaucoma at different IOP levels. Acta Ophthalmol. 1991;69:565-8)9 Figure 2 : demonstrates the probabilty of getting glaucoma (Y2) in relation to the C/D ratio (X)Y2=Y0+A1eX/T1 Y2= the probability of the incidence of POAG in the next 5 years when the C/D ratio = x2 8 (formulated from the results of Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology Apr;105(4):733-9.)6 The combined probability will take in consideration the IOP (Y1) and the C/D (Y2) ratio as the resultant outcome as shown in table1. 8 Y1+Y2 2 Early diagnosis Accordingly people are classified after calculation of the probability of getting glaucoma into the following: Normal up to 0.10 on the probability scale with normal IOP up to 21 mmHg and C/D ratio up to 0.5: (Nothing to be done) Ocular hypertension in whom the rise of IOP above 21 mmHg is the only sign with normal C/D ratio and their management will follow the general scheme of possible, probable, or definite as will be demonstrated. Possible up to 0.20 on the probability scale with rise of IOP more than 21 mmHg and increase of C/D ratio but the combined probability will not exceed 0.20.(Observation) Probable up to 0.30 on the probability scale (these has to be treated and observed) a monotherapy may be sufficient to achieve the target IOP Highly probable up to 0.40 on the probability scale (treatment vigorously and observe) a bi-therapy may be needed to achieve the target IOP Definite more than 0.40 on the probability scale (full tolerable treatment, laser or surgery and observe to achieve the target IOP) Web Page: Tel: ,